Sugi Predict

Sugi Predict / Targets / POLA1

POLA1

DNA polymerase alpha catalytic subunit · P09884 · POLA1 on Sugi Atlas →

46,804 patent compounds predicted against POLA1, 33,988 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Aphidicolin Aphidicolin (SCHEMBL183956) 1.00 7/20
SCHEMBL15747 SCHEMBL15747 0.61 7/20
SCHEMBL280198 SCHEMBL280198 1.00 6/20
SCHEMBL445153 SCHEMBL445153 0.50 6/20
SCHEMBL445154 SCHEMBL445154 0.50 6/20
Podocaric Acid Podocaric Acid (SCHEMBL160062) 0.72 4/20
SCHEMBL267750 SCHEMBL267750 0.60 4/20
Ecabet Ecabet (SCHEMBL373030) 0.56 4/20
Ecabet Ecabet (SCHEMBL437091) 0.55 4/20
SCHEMBL279978 SCHEMBL279978 0.49 4/20
SCHEMBL280128 SCHEMBL280128 0.49 4/20
SCHEMBL151741 SCHEMBL151741 0.46 4/20
SCHEMBL151742 SCHEMBL151742 0.46 4/20
SCHEMBL151743 SCHEMBL151743 0.46 4/20
SCHEMBL280071 SCHEMBL280071 0.46 4/20
SCHEMBL393640 SCHEMBL393640 0.43 4/20
SCHEMBL266932 SCHEMBL266932 0.42 4/20
SCHEMBL267305 SCHEMBL267305 0.42 4/20
SCHEMBL369565 SCHEMBL369565 0.71 3/20
SCHEMBL369566 SCHEMBL369566 0.71 3/20

Clinical trials — most relevant to POLA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
PREventing Progression of Adipose Tissue Redistribution PHASE4COMPLETED
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection PHASE3UNKNOWN
Intracameral Antibiotic Safety Study PHASE3SUSPENDED
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer PHASE2UNKNOWN
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer PHASE2COMPLETED
Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors PHASE2RECRUITING
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer PHASE2RECRUITING
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment PHASE2ACTIVE_NOT_RECRUITING
Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases PHASE2UNKNOWN
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer nanUNKNOWN
Cohort of Tumors With POLE/D1 Mutation nanRECRUITING
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission. nanUNKNOWN
Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome) nanCOMPLETED
REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification nanRECRUITING
Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer nanNOT_YET_RECRUITING
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Practice Based Nutrition Intervention-2 nanCOMPLETED
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease nanCOMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex nanENROLLING_BY_INVITATION
Choroid Plexus Dysfunction in Neurological Diseases nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a POLA1 binder may also engage these)

ProteinNameSimilarity
P33609 — 1.000 P33609 →
O89042 — 1.000 O89042 →
Q9DE46 — 0.996 Q9DE46 →
O00874 — 0.994 O00874 →
P28040 — 0.993 P28040 →
Q9FHA3 — 0.993 Q9FHA3 →
P27727 — 0.989 P27727 →
D3ZA12 — 0.989 D3ZA12 →
P26019 — 0.989 P26019 →
P09252 — 0.989 P09252 →
DHX29 ATP-dependent RNA helicase DHX29 0.988 landscape →
P43139 — 0.988 P43139 →
Q9QJ32 — 0.988 Q9QJ32 →
P0C972 — 0.988 P0C972 →
A3KFM7 — 0.988 A3KFM7 →
Q4JQU7 — 0.987 Q4JQU7 →
Q94636 — 0.987 Q94636 →
B6ZLK2 — 0.987 B6ZLK2 →
Q9E6N9 — 0.987 Q9E6N9 →
Q8TD26 — 0.987 Q8TD26 →
P13382 — 0.987 P13382 →
A5E3K3 — 0.987 A5E3K3 →
Q9UT24 — 0.987 Q9UT24 →
Q07205 — 0.987 Q07205 →
Q196U0 — 0.986 Q196U0 →
Q9H1H9 — 0.986 Q9H1H9 →
P87154 — 0.986 P87154 →
P24907 — 0.986 P24907 →
Q14149 — 0.986 Q14149 →
Q7PZD5 — 0.986 Q7PZD5 →